214 related articles for article (PubMed ID: 33846541)
61. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
[TBL] [Abstract][Full Text] [Related]
62. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
63. Venetoclax: A new wave in hematooncology.
Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
[TBL] [Abstract][Full Text] [Related]
64. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
[No Abstract] [Full Text] [Related]
65. Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.
Molica S; Shanafelt TD; Allsup D; Giannarelli D
Am J Hematol; 2024 Mar; 99(3):480-483. PubMed ID: 38100222
[TBL] [Abstract][Full Text] [Related]
66. Use of venetoclax combination regimens in chronic lymphocytic leukemia.
Tam CS
Clin Adv Hematol Oncol; 2021 Aug; 19(8):504-506. PubMed ID: 34411069
[No Abstract] [Full Text] [Related]
67. How I manage CLL with venetoclax-based treatments.
Wierda WG; Tambaro FP
Blood; 2020 Apr; 135(17):1421-1427. PubMed ID: 32076705
[TBL] [Abstract][Full Text] [Related]
68. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
69. Upfront therapy: the case for continuous treatment.
Tam CS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):55-58. PubMed ID: 34889433
[TBL] [Abstract][Full Text] [Related]
70. Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective.
Sönmez M; Kestane M; Akıdan O; Erkut N; Bektaş Ö
Turk J Haematol; 2021 Dec; 38(4):344-346. PubMed ID: 34792306
[No Abstract] [Full Text] [Related]
71. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.
Molina JC; Asare JM; Tuschong L; West RR; Calvo KR; Persky R; Boyce AM; Hammoud DA; Holland SM; Hickstein D; Shah NN
Pediatr Blood Cancer; 2021 Mar; 68(3):e28865. PubMed ID: 33369023
[TBL] [Abstract][Full Text] [Related]
72. An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.
Pleyer L; Sekeres MA
Lancet Haematol; 2022 Oct; 9(10):e714-e716. PubMed ID: 36063831
[No Abstract] [Full Text] [Related]
73. [Research Advance of Venetoclax in Hematological Tumors--Review].
Chen LY; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1419-1423. PubMed ID: 32798437
[TBL] [Abstract][Full Text] [Related]
74. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
[TBL] [Abstract][Full Text] [Related]
75. Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation.
Gao F; Gao Y; Luo Y; Yu J; Fu H; Lai X; Liu L; Ye B; Lan J; Song X; Lu Y; Chen L; Chen Y; Yu K; Huang H; Shi J; Zhao Y
Am J Hematol; 2022 Feb; 97(2):E44-E47. PubMed ID: 34778993
[No Abstract] [Full Text] [Related]
76. Acquired Pelger-Huet anomaly in two patients with chronic lymphocytic leukemia treated with venetoclax.
Robier C; Knaus G; Egger M
Clin Chem Lab Med; 2021 Sep; 59(10):e395-e397. PubMed ID: 33984884
[No Abstract] [Full Text] [Related]
77. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
78. Update on the CAPTIVATE trial of ibrutinib plus venetoclax.
Siddiqi T
Clin Adv Hematol Oncol; 2023 Dec; 21(12):654-657. PubMed ID: 38039059
[No Abstract] [Full Text] [Related]
79. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
80. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.
Fischer K; Al-Sawaf O; Hallek M
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):357-362. PubMed ID: 33275717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
